Your session is about to expire
← Back to Search
Monoclonal Antibodies
Benralizumab for Asthma (CHINOOK Trial)
Phase 4
Recruiting
Led By Mario Castro, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Fewer than 12 exacerbations within the 6 months prior to Visit 3
Fewer than 12 exacerbations within the 6 months prior to Visit 3.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from baseline to week 52 (visit 11)
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
Summary
This trial will help assess the effect of benralizumab on structural and lung function changes in severe asthmatics over a 48-week period.
Who is the study for?
Adults aged 18-70 with severe eosinophilic asthma, not well-controlled despite using inhaled steroids and long-acting beta agonists. They must have specific levels of blood eosinophils and less than 12 asthma attacks in the past six months. Excluded are those who've had certain treatments like benralizumab or bronchial thermoplasty recently, current smokers, cancer patients, pregnant women, or those on immunosuppressants.
What is being tested?
The trial is testing if benralizumab can improve lung structure and function over a 48-week period compared to a placebo in patients with severe eosinophilic asthma. Participants will be monitored for changes after treatment and during a four-week follow-up.
What are the potential side effects?
While not specified here, common side effects of benralizumab may include headache, sore throat, fever; rare but serious effects could involve allergic reactions or worsening breathing problems.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I've had fewer than 12 asthma attacks in the last 6 months.
Select...
I've had fewer than 12 flare-ups of my condition in the last 6 months.
Select...
I am between 18 and 70 years old.
Select...
I have asthma treated with strong medication for over a year.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from baseline to week 52 (visit 11)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from baseline to week 52 (visit 11)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The change in airway wall area percentage as the overall median for airway generations 3 and 4 combined as measured by quantitative computed tomography (QCT) imaging
The change in eosinophil numbers expressed as number/mm2 in submucosa as measured by major basic protein (MBP) staining in endobronchial biopsies
Secondary study objectives
Absolute change from baseline to End of Treatment in mucus score assessed using computed tomography (CT) scans
Absolute change in R5-R20 (peripheral airway resistance defined as the difference in resistance between 5 Hz [R5, total respiratory system resistance] and 20 Hz [R20, central resistance]) as measured by airwave oscillometry (AO)
Lung
+32 moreOther study objectives
The number of Adverse events (AEs)/serious adverse events (SAEs).
Side effects data
From 2016 Phase 3 trial • 220 Patients • NCT0207525515%
Nasopharyngitis
8%
Asthma
7%
Sinusitis
7%
Headache
7%
Bronchitis
6%
Upper respiratory tract infection
4%
Influenza
3%
Back pain
3%
Cough
3%
Dyspnoea
3%
Hypertension
3%
Rhinitis
1%
Urosepsis
1%
Nephrolithiasis
1%
Intervertebral disc protrusion
1%
Umbilical hernia
1%
Adverse drug reaction
1%
Hypersensitivity
1%
Vertigo
1%
Nausea
1%
Dermatitis atopic
1%
Urinary tract infection bacterial
100%
80%
60%
40%
20%
0%
Study treatment Arm
Benra 30 mg q.4 Weeks
Benra 30 mg q.8 Weeks
Placebo
Awards & Highlights
Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
2Treatment groups
Experimental Treatment
Placebo Group
Group I: BenralizumabExperimental Treatment1 Intervention
Administrated subcutaneously (SC) every 4 weeks for the first 3 doses, then every 8 weeks
Group II: PlaceboPlacebo Group1 Intervention
Administrated subcutaneously every 4 weeks for the first 3 doses, then every 8 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Benralizumab
2016
Completed Phase 4
~10320
Find a Location
Who is running the clinical trial?
AstraZenecaLead Sponsor
4,400 Previous Clinical Trials
289,122,676 Total Patients Enrolled
347 Trials studying Asthma
661,388 Patients Enrolled for Asthma
Mario Castro, MDPrincipal InvestigatorUniversity of Kansas School of Medicine 3901 Rainbow Blvd. Kansas City, KS 66160, USA
6 Previous Clinical Trials
2,236 Total Patients Enrolled
6 Trials studying Asthma
2,236 Patients Enrolled for Asthma
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I haven't taken immunosuppressive drugs or received blood products in the last 30 days.I've had fewer than 12 asthma attacks in the last 6 months.I haven't had certain asthma treatments or vaccines recently.My blood test shows I have high eosinophils, or I have nasal polyps, or my lung function is reduced.I've had fewer than 12 flare-ups of my condition in the last 6 months.I am between 18 and 70 years old.Your asthma is not well controlled, as shown by a questionnaire score higher than 1.5.You have to have a negative pregnancy test.Your lung function test shows that you can breathe out a certain amount of air, but not as much as expected for someone your age and size.I do not smoke or have a history of serious health issues that could affect the study.I have asthma treated with strong medication for over a year.
Research Study Groups:
This trial has the following groups:- Group 1: Placebo
- Group 2: Benralizumab
Awards:
This trial has 2 awards, including:- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger